ExpandAmong adults aged 18–44 undergoing a first colorectal cancer (CRC) screening, a pre-screening AST below 14 U/L was associated with a 65% higher likelihood of an early-onset CRC diagnosis, and an ALT below 14 U/L with a 68% higher likelihood, each compared with patients whose values fell in the range of 14–29 U/L.
ExpandAmong adults aged 18–44 undergoing a first colorectal cancer (CRC) screening, a pre-screening AST below 14 U/L was associated with a 65% higher likelihood of an early-onset CRC diagnosis, and an ALT below 14 U/L with a 68% higher likelihood, each compared with patients whose values fell in the range of 14–29 U/L.
ExpandThe self-pay share of encounters rose in all four care settings studied between early 2022 and early 2026, but unevenly: the increase was steepest in the emergency department (5.5% to 7.6%), more modest for inpatient admissions (1.9% to 2.6%) and births (0.8% to 1.3%), and moved just a little in primary care (1.8% to 1.9%).
ExpandCompared with patients who had no neurodevelopmental diagnosis, patients with autism (ASD), ADHD, or both were more likely to have a connective tissue disorder diagnosis.
ExpandMost Patient Health Questionnaire-9 (PHQ-9) responses, which are primarily patient entered, were submitted during the day; submission volumes peaked mid-morning and were lowest overnight, with only about 2.5% of submissions between 11 p.m. and 5:59 a.m.
ExpandMost Patient Health Questionnaire-9 (PHQ-9) responses, which are primarily patient entered, were submitted during the day; submission volumes peaked mid-morning and were lowest overnight, with only about 2.5% of submissions between 11 p.m. and 5:59 a.m.
ExpandAmong adults without diabetes who lost weight during their first year on a GLP-1 medication, most sustained that loss into the second year. At the two-year mark, 53.1% of semaglutide patients and 52.9% of tirzepatide patients had maintained their weight within a narrow band of their one-year weight, and a further 31.9% (semaglutide) and 39.3% (tirzepatide) had lost even more.
ExpandAmong adults without diabetes who lost weight during their first year on a GLP-1 medication, most sustained that loss into the second year. At the two-year mark, 53.1% of semaglutide patients and 52.9% of tirzepatide patients had maintained their weight within a narrow band of their one-year weight, and a further 31.9% (semaglutide) and 39.3% (tirzepatide) had lost even more.
ExpandAmong adults with diabetes who lost weight during their first year on a GLP-1 medication, most maintained or extended that loss when the GLP-1 was continued into the second year. At the two-year mark, 37.7% of semaglutide patients and 47.3% of tirzepatide patients had maintained their weight loss, and another 35.4% and 38.6%, respectively, had continued to lose weight.
ExpandAmong adults with diabetes who lost weight during their first year on a GLP-1 medication, most maintained or extended that loss when the GLP-1 was continued into the second year. At the two-year mark, 37.7% of semaglutide patients and 47.3% of tirzepatide patients had maintained their weight loss, and another 35.4% and 38.6%, respectively, had continued to lose weight.
ExpandAmong patients newly diagnosed with Parkinson’s disease, 90.2% were aged 60 or older at diagnosis, with a median diagnosis age of 73. Diagnoses before age 50 were rare, accounting for 2.6% of patients.
ExpandAmong patients newly diagnosed with Parkinson’s disease, 90.2% were aged 60 or older at diagnosis, with a median diagnosis age of 73. Diagnoses before age 50 were rare, accounting for 2.6% of patients.
ExpandMale patients aged 10 to 15 who had an ED visit for a motor vehicle crash (MVC) were as much as four times as likely to experience a subsequent firearm injury compared with those whose ED visit was for a fall, in some parts of the United States.
ExpandThe risks of myocardial infarction (MI), ischemic stroke, and hemorrhagic stroke are increased for patients with high or low average systolic blood pressure (BP). The risks are greater at very low systolic BP than at very high systolic BP.
ExpandAt 24 months post-cessation, 56% of semaglutide, 52% of liraglutide, and 55% of tirzepatide patients kept the weight off or lost additional weight.
ExpandMale patients aged 10 to 15 who had an ED visit for a motor vehicle crash (MVC) were as much as four times as likely to experience a subsequent firearm injury compared with those whose ED visit was for a fall, in some parts of the United States.
ExpandThe risks of myocardial infarction (MI), ischemic stroke, and hemorrhagic stroke are increased for patients with high or low average systolic blood pressure (BP). The risks are greater at very low systolic BP than at very high systolic BP.
ExpandAt 24 months post-cessation, 56% of semaglutide, 52% of liraglutide, and 55% of tirzepatide patients kept the weight off or lost additional weight.
ExpandUnder the 2026 cholesterol treatment guideline, 54.6% of adults aged 20–79 without established cardiovascular disease were eligible for lipid-lowering therapy, compared with 41.3% under the 2018 guideline, a 13.3 percentage-point increase in the treatment-eligible share.
ExpandMale patients aged 10 to 15 who had an ED visit for a motor vehicle crash (MVC) were as much as four times as likely to experience a subsequent firearm injury compared with those whose ED visit was for a fall, in some parts of the United States.
ExpandThe risks of myocardial infarction (MI), ischemic stroke, and hemorrhagic stroke are increased for patients with high or low average systolic blood pressure (BP). The risks are greater at very low systolic BP than at very high systolic BP.
ExpandAt 24 months post-cessation, 56% of semaglutide, 52% of liraglutide, and 55% of tirzepatide patients kept the weight off or lost additional weight.
